bluuebunny/crossref_metadata_2025_split huggingface dataset:
Recommendations on the use of the flash continuous glucose monitoring system in hospitalized patients with diabetes in Latin America
Authors: Gómez Ana María , Henao Carrillo Diana Cristina , Ré Matías Alberto , Faradji Raquel N. , Flores Caloca Oscar , de la Garza Hernández Natalia Eloísa , Antillón Ferreira Carlos , Garnica-Cuéllar Juan C. , Krakauer Marcio , Galindo Rodolfo J. 
Published: June 2024

AbstractBackgroundContinuous glucose monitoring can improve glycemic control for hospitalized patients with diabetes, according to current evidence. However, there is a lack of consensus-established recommendations for the management of hospitalized patients with diabetes using flash continuous glucose monitoring system (fCGM) in Latin America. Therefore, this expert consensus exercise aimed to establish guidelines on the implementation of fCGM in the management of hospitalized patients with diabetes in Latin America.MethodsThe modified Delphi method was applied on a panel of nine specialists, establishing consensus at 80%. A twenty-two-question instrument was developed to establish recommendations on the use of fCGM in hospitalized patients living with diabetes.ResultsBased on consensus, experts recommend the use of fCGM in hospitalized patients with diabetes starting at admission or whenever hyperglycemia (> 180 mg/dl) is confirmed and continue monitoring throughout the entire hospital stay. The recommended frequency of fCGM scans varies depending on the patient's age and diabetes type: ten scans per day for pediatric patients with type 1 and 2 diabetes, adult patients with type 1 diabetes and pregnant patients, and seven scans for adult patients with type 2 diabetes. Different hospital services can benefit from fCGM, including the emergency room, internal medicine departments, intensive care units, surgery rooms, and surgery wards.ConclusionsThe use of fCGM is recommended for patients with diabetes starting at the time of admission in hospitals in Latin America, whenever the necessary resources (devices, education, personnel) are available.
Temperature effect on coagulation function in mild hypothermic patients undergoing thoracic surgeries: thromboelastography (TEG) versus standard tests
Authors: Hui Shangyi , Zhang Qian , Lang Jiaxin , Yi Jie 
Published: June 2024

Abstract
Purpose
Our previous research has revealed that mild hypothermia leads to excessive bleeding in thoracic surgeries, while the underlying mechanism stayed unrevealed by the standard coagulation tests. The research question in this study was as follows: “How does mild hypothermia impair the hemostatic function in patients receiving thoracic surgeries?”. The purpose was to detect the disturbed coagulation processes by comparing the TEG parameters in patients receiving active vs. passive warming during thoracic surgeries.

Methods
Standard coagulation tests and thromboelastography (TEG) were adopted to compare the hemostatic functions in patients receiving active vs. passive warming during thoracic surgeries. Furthermore, blood samples from passive warming group were retested for TEG at actual core body temperatures.

Results
Sixty-four eligible patients were included in this study. TEG revealed that mild hypothermia significantly disturbed coagulation by decreasing MA (59.4 ± 4.5 mm vs. 64.2 ± 5.7 mm, p = 0.04) and α angle (70.4 ± 5.2° vs. 74.9 ± 4.4°, p = 0.05) and prolonging ACT (122.2 ± 19.3 s vs. 117.3 ± 15.2 s, p = 0.01) and K time (1.9 ± 1.0 s vs. 1.3 ± 0.4 min, p = 0.02). TEGs conducted under core body temperatures revealed more impaired coagulation than those incubated at 37 °C. Furthermore, postoperative shivering and waking time were significantly increased in mild hypothermic patients.

Conclusion
Mild hypothermia significantly impaired coagulation function in patients receiving thoracic surgeries, which could be detected by TEGs other than the standard coagulation tests. Temperature-adjusted TEGs may provide a preferable method of hemostatic monitoring and transfusion guidance in thoracic surgeries, which warrants further clinical investigations.
Impact of annual trend volume of low-dose computed tomography for lung cancer screening on overdiagnosis, overmanagement, and gender disparities
Authors: Hsin-Hung Chen , En-Kuei Tang , Yun-Ju Wu , Fu-Zong Wu 
Published: June 2024

Abstract
Background
With the increasing prevalence of nonsmoking-related lung cancer in Asia, Asian countries have increasingly adopted low-dose computed tomography (LDCT) for lung cancer screening, particularly in private screening programs. This study examined how annual LDCT volume affects lung cancer stage distribution, overdiagnosis, and gender disparities using a hospital-based lung cancer database.

Methods
This study analyzed the annual utilized LDCT volume, clinical characteristics of lung cancer, stage shift distribution, and potential overdiagnosis. At the individual level, this study also investigated the relationship between stage 0 lung cancer (potential strict definition regarding overdiagnosis) and the clinical characteristics of lung cancer.

Results
This study reviewed the annual trend of 4971 confirmed lung cancer cases from 2008 to 2021 and conducted a link analysis with an LDCT imaging examination database over these years. As the volume of lung cancer screenings has increased over the years, the number and proportion of stage 0 lung cancers have increased proportionally.
Our study revealed that the incidence of stage 0 lung cancer increased with increasing LDCT scan volume, particularly during the peak growth period from 2017 to 2020. Conversely, stage 4 lung cancer cases remained consistent across different time intervals. Furthermore, the increase in the lung cancer screening volume had a more pronounced effect on the increase in stage 0 lung cancer cases among females than it had among males. The estimated potential for overdiagnosis brought about by the screening process, compared to non-participating individuals, ranged from an odds ratio of 7.617 to one of 17.114. Both strict and lenient definitions of overdiagnosis (evaluating cases of stage 0 lung cancer and stages 0 to 1 lung cancer) were employed.

Conclusions
These results provide population-level evidence of potential lung cancer overdiagnosis in the Taiwanese population due to the growing use of LDCT screening, particularly concerning the strict definition of stage 0 lung cancer. The impact was greater in the female population than in the male population, especially among females younger than 40 years.
To improve lung cancer screening in Asian populations, creating risk-based prediction models for smokers and nonsmokers, along with gender-specific strategies, is vital for ensuring survival benefits and minimizing overdiagnosis.
Physical activity cut-points for older adults using the Zio XT onboard accelerometer
Authors: Etzkorn Lacey H. , Davoudi Anis , Dooley Erin E. , Gabriel Kelley P. , Chen Lin Yee , Crainiceanu Ciprian M. , Schrack Jennifer A. , Wanigatunga Amal A. 
Published: June 2024

Abstract
Introduction
The Zio® XT continuous ambulatory electrocardiographic monitor (Zio) contains an accelerometer that can help quantify an individual’s physical activity in the free-living environment.

Purpose
(1) To estimate activity cut-points to estimate daily time spent performing very light, light, or moderate to vigorous physical activity (VLIPA, LIPA, MVPA) for the Zio accelerometer. (2) To describe how Zio’s 24-h wear protocol affects estimates of daily MVPA relative to a waist-worn accelerometer’s waking-wear protocol.

Methods
Three hundred eighty one participants from the Atherosclerosis Risk in Communities (ARIC) study wore a waist-mounted ActiGraph GT3X (except while sleeping or water-based activities) and a Zio (24-h) simultaneously for three to seven days. For each person-minute, physical activity was summarized as the Mean Amplitude Deviation (MAD) for the Zio and Vector Magnitude Counts (VMC) for the GT3X. Cut points previously used in ARIC were mapped from GT3X VMC to Zio MAD using a conditional two-sample quantile–quantile approach.

Results
Evenson VMC cut-points for the GT3X (VLIPA≥76, LIPA≥903, MVPA≥2075 counts/min) were mapped to MAD for Zio (9.04, 28.2, and 58.1 mili-g). Daily hours spent in each intensity category were each strongly correlated (ICC > 0.7) between summaries produced by Zio and GT3X when restricting estimates to overlapping wear time. Zio and GT3X-estimated MVPA had high agreement (ICC = 0.77) when using device-specific wear time, but Zio measured one hour more of daily LIPA and VLIPA (95% CI = 0.83, 1.07 hrs/day).

Conclusions
We recommend the use of our cut-points for clinical research with Zio accelerometry in populations of older adults.
Pre- and post-hemodialysis differences in heart failure diagnosis by current heart failure guidelines in patients with end-stage renal disease
Authors: Kim Bong-Joon , Bae Su-Hyun , Kim Soo-Jin , Im Sung-Il , Kim Hyunsu , Heo Jung-Ho , Shin Ho Sik , Kim Ye Na , Jung Yeonsoon , Rim Hark 
Published: June 2024

Abstract
Background
Patients with end-stage renal disease (ESRD) who are on hemodialysis (HD) have reduced vascular compliance and are likely to develop heart failure (HF). In this study, we estimated the prevalence of HF pre- and post-HD in ESRD using the current guidelines.

Methods
We prospectively investigated HF in ESRD patients on HD using echocardiography pre- and post-HD. We used the structural and functional abnormality criteria of the 2021 European Society of Cardiology guidelines.

Results
A total of 54 patients were enrolled. The mean age was 62.6 years, and 40.1% were male. Forty-five patients (83.3%) had hypertension, 28 (51.9%) had diabetes, and 20 (37.0%) had ischemic heart disease. The mean N-terminal-pro brain natriuretic peptide BNP (NT-proBNP) level was 12,388.8 ± 2,592.2 pg/dL. The mean ideal body weight was 59.3 kg, mean hemodialysis time was 237.4 min, and mean real filtration was 2.8 kg. The mean left ventricular ejection fraction (LVEF) was 62.4%, and mean left ventricular end-diastolic diameter was 52.0 mm in pre-HD. Post-HD echocardiography showed significantly lower left atrial volume index (33.3 ± 15.9 vs. 40.6 ± 17.1, p = 0.030), tricuspid regurgitation jet V (2.5 ± 0.4 vs. 2.8 ± 0.4 m/s, p < 0.001), and right ventricular systolic pressure (32.1 ± 10.3 vs. 38.4 ± 11.6, p = 0.005) compared with pre-HD. There were no differences in LVEF, E/E′ ratio, or left ventricular global longitudinal strain. A total of 88.9% of pre-HD patients and 66.7% of post-HD patients had either structural or functional abnormalities in echocardiographic parameters according to recent HF guidelines (p = 0.007).

Conclusions
Our data showed that the majority of patients undergoing hemodialysis satisfy the diagnostic criteria for HF according to current HF guidelines. Pre-HD patients had a 22.2% higher incidence in the prevalence of functional or structural abnormalities as compared with post-HD patients.
Efficient large-scale 3D gravity modeling using a fast evaluate kernel matrix combined with compressed matrix techniques
Authors: Wang Xulong , He Zhanxiang , Liu Jianxin , Li Jian , Li Kun 
Published: June 2024

A fast calculated kernel matrix method is coupled with a compressed matrix technique to solve the large-scale gravity forward-modeling problem. This method accelerates the coefficient matrix computation by reducing the arctangent, logarithm, and multiplication functions in the prismatic gravity analytical expression. In addition, the use of the compressed matrix technique presents a significant advantage in that it does not require the storage of redundant kernel matrices, further reducing the memory requirements and computation time. Moreover, the discrete convolution of the compressed matrix with density is executed through the 2D fast Fourier transform (FFT). Two typical synthetic models are used to test the performance of the novel algorithm. The results demonstrate that the developed algorithm is approximately 15 times faster than the traditional algorithm. Concurrently, it demands almost 1/7th of the memory while ensuring equivalent computational accuracy. To further illustrate the capability of the algorithm, we apply our method to the terrain correction of an airborne gravity data set using a real digital elevation model. Our approach efficiently calculates 250,000 observation points across 25 million cells in only 5.42 s, compared with 234.81 s for the latest 2D Gauss-FFT method.
Acoustic full-waveform inversion on land surveys: A case study on the Qademah fault, Saudi Arabia
Authors: Zhou Wei , Hanafy Sherif M. 
Published: June 2024

Geophysical methods have been used to map a Qademah fault near a residential area in western Saudi Arabia. However, the location and spatial extension of the fault zone are still uncertain due to the limited resolution and length of geophysical surveys. We apply seismic full-waveform inversion (FWI) to a land survey 2 km in length, the result of which reveals more details of the fault as well as the subsurface. Before inversion, we remove the surface waves, converted waves, and other elastic phenomena in the f- k domain and normalize the trace amplitude to compensate for attenuation, such that wavefield modeling for FWI can be approximated by acoustic propagators with constant density. Due to the large wavefield amplitudes near the source-receiver positions, the FWI velocity gradient presents a singular zone in the near surface, which is muted to stabilize the inversion. We also invert the short-offset traces before the larger-offset traces to avoid cycle skipping at the far offsets and obtain a reasonable data fit despite some mismatches in the near offsets. The final FWI velocity model shows the Qademah fault at approximately 1000 m distance as well as three low-velocity anomalies at 100 m depth, confirmed by first-arrival traveltime tomography. We also observe a potential low-velocity layer at 250–300 m depth, which was not reported in former studies. This model can also be used for geologic interpretation, hazard assessment, and paleoseismology studies of the local area.
Neuropathy trajectory informed by algorithm-based alerts from remote symptom monitoring (RSM) tool in breast cancer practice.
Authors: Saltzman Joel N. , Rusli Emelly , Galaznik Aaron , Wujcik Debra 
Published: June 2024

11114 Background: The prevalence of chemotherapy-induced peripheral neuropathy (CIPN) ranges from 19% to over 85%1. In breast cancer (BC) adjuvant treatment, 40% of women report numbness and tingling after two years with 10% stating the symptoms are severe2. Risk factors include age, pre-existing neuropathy (PN), and treatment with taxanes and platinum-based drugs. This study explored the trajectory of neuropathy in data from remote symptom monitoring (RSM) in breast cancer practice. Methods: Women undergoing BC treatment who enrolled in Carevive PROmPT, an RSM tool, between 9/1/2020 and 11/29/2023 were included. A composite score (derived from PRO-CTCAE) using presence, severity, and interference reports symptoms as mild, moderate or severe. Mild symptoms are discussed at the next clinical visit while moderate/severe symptoms trigger an alert to the care team for immediate evaluation and mitigation. Analysis of neuropathy trajectory was conducted in patients who did not have PN at baseline, examining time to first neuropathy report and time to alert trigger due to severity. Age at first neuropathy, duration of therapy, cancer stage, race, CIPN drugs use, and the level of neuropathy interference was explored. Results: A total of 519 BC patients with one or more alerts were included, of whom 177 (34.1%) reported moderate/severe neuropathy at least once. Of 7,641 total alerts generated, 10.5% were associated with neuropathy. Nearly 40% (n=74) of patients had PN, with median age was 58.5, 31% late stage, 32% Black/African American, and 61% having prior CIPN treatment. About 58.2% of patients (n=103) did not have PN at baseline; of whom neuropathy was first reported over a median of 42 days (IQR: 17.5, 70.5) from baseline and 53.4% of patients (n=55) had mild neuropathy at first report, which then progressed to moderate/severe at a median of 28 days (IQR: 14, 79). About half of patients (52%) described the first neuropathy interference to be a little bit or somewhat. Patients with mild first occurrence of neuropathy (n=55) were then stratified by time to first neuropathy alert (moderate/severe) from first report: 0-28 days (n=28) and >28 days (n=27). For the two groups, median age at first neuropathy was 51 and 49, duration of treatment was 2.4 and 4.4 months, late stage was 18% and 15%, Black/African American 32% and 22%, and receiving CIPN drugs at alert was 24% and 29%, respectively. The most prevalent level of interference upon alert was described as somewhat (32% vs. 28%, respectively). Conclusions: Breast cancer patients are at risk for developing severe and sustained neuropathy. Patients without PN whose first report of neuropathy was mild, quickly progressed to moderate/severe neuropathy. Physician notification at first report of neuropathy rather than with an alert of moderate/severe neuropathy provides opportunity for earlier intervention and better outcomes.
Beamion LUNG-2: A phase III randomized controlled trial of zongertinib (BI 1810631) versus standard of care (SoC) in patients with locally advanced/metastatic non-squamous non-small cell lung cancer (NSCLC) harboring HER2 tyrosine kinase domain (TKD) mutations.
Authors: Johnson Melissa Lynne , Soo Ross A. , Wu Yi-Long , Baktash Navid , Maier Daniela , Eigenbrod-Giese Sabina , Yoshida Tatsuya 
Published: June 2024

TPS8654 Background: HER2mutations are present in 2–4% of NSCLC tumors, and ~50% occur in the TKD. First-line SoC for patients with HER2mutation-positive (m+) NSCLC is platinum-based chemotherapy ± immunotherapy; however, no targeted first-line treatment has been approved. Zongertinib is a HER2-selective tyrosine kinase inhibitor (TKI) that binds to both wild-type and mutated HER2 but spares EGFR. In a Phase Ia trial in 53 pre-treated patients with HER2 aberration-positive solid tumors, zongertinib conferred an objective response (OR)/disease control rate (DCR) of 49/91% and an OR/DCR of 58/97% in those patients with HER2m+ NSCLC (n=36), with manageable safety with few EGFR-associated toxicities (Beamion LUNG-1; NCT04886804). Here, we describe Beamion LUNG-2 (NCT06151574), a Phase III, randomized, active-controlled, open-label trial designed to assess the efficacy of first-line zongertinib versus SoC in patients with HER2m+, locally advanced or metastatic non-squamous NSCLC. Methods: Approximately 270 patients from ~160 sites across 30 countries will be randomized 1:1 to receive either zongertinib or SoC and stratified by the presence of the A775_G77insYVMA HER2 mutation. In the experimental treatment arm, patients will receive 120 mg oral zongertinib once-daily in 21-day cycles. In the comparator treatment arm, patients will receive 500 mg/m2 intravenous pemetrexed chemotherapy, plus either 75 mg/m2 cisplatin or Area Under the Curve 5 carboplatin, plus 200 mg pembrolizumab on Day 1 once every 3 weeks (q3w) for four 21-day cycles, then maintenance with 500 mg/m2 pemetrexed plus 200 mg pembrolizumab q3w for up to 35 cycles. Treatment in both arms will continue until progressive disease (PD; RECIST 1.1), undue toxicity, or other criteria are met. The primary endpoint is progression-free survival (RECIST 1.1), by blinded central independent review. Secondary endpoints include OR (defined as best overall response of complete or partial response, RECIST 1.1); patient-reported outcomes analysed as changes from baseline to Week 25; overall survival and occurrence of adverse events (CTCAE version 5.0). Key inclusion criteria are histologically or cytologically diagnosed advanced and/or metastatic non-squamous NSCLC; ≥1 measurable lesion (RECIST 1.1); no prior systemic treatment for locally advanced or metastatic disease; a documented HER2 TKD mutation; and eligibility to receive the selected SoC. Key exclusion criteria are tumors with targetable alterations with an available treatment; presence/history of uncontrolled/symptomatic leptomeningeal disease; and radiotherapy or major surgery ≤4 weeks prior to randomization. Clinical trial information: NCT06151574 .
REZILIENT2: Phase 2 study of zipalertinib in patients with advanced non-small cell lung cancer (NSCLC) with exon 20 insertions (ex20ins) and other uncommon epidermal growth factor receptor (EGFR) mutations.
Authors: Yu Helena Alexandra , Besse Benjamin , Nishio Makoto , Cheng Ying , Wei Li , Wacheck Volker , Heymach John 
Published: June 2024

TPS8670 Background: Patients with NSCLC harboring uncommon EGFR mutations, including ex20ins, have limited treatment options. Zipalertinib (CLN-081/TAS6417) is an oral tyrosine kinase inhibitor of EGFR with broad activity against EGFRmutations (including ex20ins) and increased selectivity for ex20ins versus wild-type EGFR. Zipalertinib has shown preclinical activity against a wide spectrum of EGFR ex20ins mutations and other uncommon EGFR mutations. In a phase 1/2a study (REZILIENT1), encouraging antitumor activity and an acceptable safety profile were observed in heavily pretreated patients with EGFRex20ins–mutant NSCLC, leading to ‘Breakthrough Therapy’ designation from the U.S. Food and Drug Administration. The aim of REZILIENT2 is to evaluate the efficacy and safety of zipalertinib in patients with NSCLC harboring EGFRex20ins and other uncommon single or compound EGFR mutations, including patients with brain metastases and leptomeningeal disease (LMD). Methods: In this global, phase 2b, open-label, multicohort study (NCT05967689), adult patients with locally advanced or metastatic NSCLC will be assigned to one of four cohorts depending on prior treatment and type of EGFR mutation: A) patients with EGFR ex20ins mutations who have progressed on or after first-line platinum-based chemotherapy and prior therapy targeting ex20ins (administered together or separately) for advanced disease; B) patients with EGFR ex20ins mutations who have not received prior treatment for advanced disease; C) patients with ex20ins or other uncommon single or compound EGFR mutations and active central nervous system metastases (including LMD) who may or may not have received prior treatment for advanced disease; and D) patients harboring other uncommon non-ex20ins single or compound EGFR mutations who have progressed on or after standard systemic therapy. Patients will receive zipalertinib at a starting dose of 100 mg orally twice daily, which will continue on a 21-day cycle until progression, unacceptable toxicity, or other discontinuation criteria are met. The primary endpoint is investigator-assessed objective response rate per Response Evaluation Criteria in Solid Tumours, version 1.1. Secondary endpoints include disease control rate, duration of response, progression-free survival, overall survival, intracranial efficacy per Response Assessment in Neuro-Oncology Brain Metastases (cohort C), safety and tolerability, and pharmacokinetics. Estimated enrollment is 40 patients per cohort (total 160), with potential expansion to ~100 patients per cohort if predefined threshold criteria of efficacy are met. Enrollment began in July 2023. Clinical trial information: NCT05967689 .